Peak Bio, Inc. (PKBO)

NASDAQ: PKBO · IEX Real-Time Price · USD
5.92
-0.59 (-9.00%)
Dec 6, 2022 2:18 PM EST - Market open
-9%
Market Cap 130.58M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 8.30M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,937
Open 6.38
Previous Close 6.51
Day's Range 5.74 - 6.38
52-Week Range 3.8 - 15
Beta n/a
Analysts Buy
Price Target 15.30 (+158.3%)
Earnings Date n/a

About PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto... [Read more]

Industry Biotechnology
Founded 2020
Employees 30
Stock Exchange NASDAQ
Ticker Symbol PKBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PKBO stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 158.27% from the latest price.

Price Target
$15.3
(158.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What Is Going on With Peak Bio (PKBO) Stock Today?

It has been a bumpy week and this Friday isn't any easier following the monthly jobs report. However, that doesn't seem to matter for Peak Bio (NASDAQ: PKBO ), which recently combined in a deal with Ign...

1 month ago - InvestorPlace

Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital

Peak Bio, Inc. ("Peak Bio" or the "Company") (NASDAQ: PKBO), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory disea...

1 month ago - Business Wire

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

NEW YORK--(BUSINESS WIRE)--Peak Bio Co., Ltd.

1 month ago - Business Wire